{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:49:54Z","timestamp":1761126594863},"reference-count":32,"publisher":"American Society of Consultant Pharmacists","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.4140\/tcp.n.2005.1036","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:06:55Z","timestamp":1294884415000},"page":"1036-1055","source":"Crossref","is-referenced-by-count":3,"title":["Ibandronate: A New Oral Bisphosphonate for Postmenopausal Osteoporosis"],"prefix":"10.4140","volume":"20","author":[{"given":"David R. P.","family":"Guay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2004.09.004","article-title":"The role of bisphosphonates in breast cancer","volume":"13","author":"R Coleman","year":"2004","journal-title":"Breast"},{"key":"2","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2004.07.024","article-title":"Bisphosphonates in the treatment of skeletal metastases","volume":"31","author":"P Conte","year":"2004","journal-title":"Semin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1191\/0269216304pm914ra","article-title":"Systematic review of bisphosphonates for hypercalcemia of malignancy","volume":"18","author":"Y Sauders","year":"2004","journal-title":"Pall Med"},{"key":"4","first-page":"462","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"17","author":"P Delmas","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"5","volume-title":"Ibandronate (Boniva) product information","year":"2005"},{"key":"6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacokinetic update","volume":"44","author":"J Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"R Muhlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"F Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001813-200502000-00001","article-title":"Ibandronate in metastatic bone disease: a review of preclinical data","volume":"16","author":"F Bauss","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S8756-3282(01)00665-2","article-title":"Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis","volume":"30","author":"P Ravn","year":"2002","journal-title":"Bone"},{"key":"11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomized, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"R Coleman","year":"1999","journal-title":"Ann Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jpba.2005.03.020","article-title":"Analytical methods for the quantification of ibandronate in body fluids and bone","volume":"39","author":"R Endele","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"13","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1210\/jc.2004-1750","article-title":"Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study","volume":"90","author":"J Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/17.7.1281","article-title":"Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study","volume":"17","author":"R Bergner","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(03)00091-7","article-title":"Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens","volume":"32","author":"L Tanko","year":"2003","journal-title":"Bone"},{"key":"16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Change in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment","volume":"22","author":"P Ravn","year":"1998","journal-title":"Bone"},{"key":"17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"P Ravn","year":"1996","journal-title":"Bone"},{"key":"18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"M McClung","year":"2004","journal-title":"J Bone Min Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S8756-3282(03)00033-4","article-title":"The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast","volume":"32","author":"L Tanko","year":"2003","journal-title":"Bone"},{"key":"20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"C Chestnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"P Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE","volume":"21","author":"C Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"23","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"B Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women","volume":"254","author":"L Tanko","year":"2003","journal-title":"J Int Med"},{"key":"25","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/jc.2003-022029","article-title":"Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis","volume":"88","author":"C Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"P Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"D Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies","volume":"90","author":"J Body","year":"2004","journal-title":"Br J Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"J Body","year":"2004","journal-title":"Pain"},{"key":"30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study","volume":"15","author":"R Recker","year":"2004","journal-title":"Osteoporos Int"},{"key":"31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00198-004-1662-x","article-title":"Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women","volume":"16","author":"L Tanko","year":"2005","journal-title":"Osteoporos Int"},{"key":"32","volume-title":"Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy","author":"E DeCock","year":"2005"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:04:06Z","timestamp":1559937846000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2005\/00000020\/00000012\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12,1]]}},"alternative-id":["K55U5M08083N541J"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2005.1036","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}